Cystatin C Assay Market Size Worth $590.29 Million By 2032 | CAGR: 7.1%

The global cystatin C assay market size is expected to reach USD 590.29 million by 2032, according to a new study by Polaris Market Research. The report “Cystatin C Assay Market Share, Size, Trends, Industry Analysis Report, By Product (Kits, Reagents, and Analyzers); By Sample Type; By Method; By Application; By End-user; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing prevalence of chronic kidney disease (CKD) and rising geriatric population are some of the major factors driving the growth of the cystatin C assay market. Lower kidney function can lead to various health problems, such as anemia, weak immunity, appetite loss, and low calcium levels. An increasing concern over these health problems is increasing the demand for cystatin C assays. Moreover, the high risk of CKD among patients with diabetes, hypertension, and heart diseases and the increasing prevalence and mortality rate of these diseases will positively impact the market growth in the coming years. For instance, according to the Centers for Disease Control & Prevention (CDC), in 2021, in the U.S., hypertension was a major cause of 691,095 deaths.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/cystatin-c-assay-market/request-for-sample

Cystatin C testing is gaining significant popularity due to its many advantages over creatinine testing. For instance, cystatin C is not affected by body mass or diet of an individual which makes it a reliable marker of kidney function. Moreover, the strong emphasis of the government to increase the expenditure on kidney-related diseases and the growing patient population suffering from kidney diseases are expected to propel the demand for cystatin C tests, thereby spurring market growth. 

An increasing awareness related to the benefits of early screening of kidney disease will prove beneficial for the growth of the cystatin C assay market. Moreover, the accurate results and greater reliability of cystatin C tests in people with extreme obesity, liver cirrhosis, amputated limbs, and decreased muscle mass will increase its preference over the creatinine test. Furthermore, patients suffering from Glomerulonephritis are expected to increase the chances of end-stage kidney disease, thereby creating a demand for cystatin C assay. For instance, according to the U.S. Renal Data System (USRDS), in 2020, Glomerulonephritis held a 15.0% share among the major causes of end-stage kidney disease.

Cystatin C Assay Market Report Highlights

• The kits segment dominated the market, as it serves the need for a comprehensive solution for carrying out the cystatin C assay.
• The blood segment accounted for the largest share of the market, owing to the higher preference for blood samples by healthcare facilities and clinical laboratories.  
• The enzyme-linked immunosorbent assay (ELISA) segment held the largest market share, owing to factors such as simpler processes and easy availability of ELISA tests.
• Diagnostics segment dominated the market, owing to an increasing demand for early screening tests for chronic kidney disease (CKD).
• North America accounted for the largest market share, owing to the high burden of chronic kidney disease and sophisticated healthcare system.
• The market players include Roche Diagnostics Limited, Siemens Healthineers AG, Abbott, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., bioMérieux, S.A, and others.

Polaris Market Research has segmented the cystatin C assay market report based on product, sample type, method, application, end-user, and region:

Cystatin C Assay, Product Outlook (Revenue - USD Million, 2019 - 2032)

• Kits
• Reagents
• Analyzers

Cystatin C Assay, Sample Type Outlook (Revenue - USD Million, 2019 - 2032)

• Blood
• Urine

Cystatin C Assay, Method Outlook (Revenue - USD Million, 2019 - 2032)

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Particle-Enhanced Nephelometric Immunoassay (PENIA)
• Chemiluminescent Immunoassay (CLIA)
• Immunofluorescence Assay
• Others

Cystatin C Assay, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Diagnostics
• Research

Cystatin C Assay, End-user Outlook (Revenue - USD Million, 2019 - 2032)

• Hospitals
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Others

Cystatin C Assay, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of LA
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Cystatin C Assay Market Report Scope